Celldex Therapeutics, Inc.
Price data unavailable
Track CLDX in your trading journalAbout Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc. (CLDX) is a US-listed equity tracked across major market indices. Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
The company reports trailing twelve-month revenue of $1.76M and net loss of $78.69M. Key metrics include a return on equity of -17.3%, a debt-to-equity ratio of 0.12.
FINOTAUR provides free research summaries, news aggregation, and fundamentals for CLDX to support both active traders and long-term investors.
Fundamentals
| Revenue (TTM) | $1.76M |
| Net Income (TTM) | $-78.69M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | -17.25% |
| Debt-to-Equity | 0.12 |
| Dividend per Share | — |
Recent News
- GlobeNewswire Inc.·Apr 6
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- GlobeNewswire Inc.·Apr 2
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
- GlobeNewswire Inc.·Mar 1
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
Want real-time analysis on CLDX?
Track it free in your trading journal. Log trades, tag setups, and review your edge.